A clinical trial has seen promising results from a new class of medication to treat hypertension. Design by MNT; Photography by Peca King/500px/Getty Images & MementoJpeg/Getty Images Blood pressure ...
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a ...
CHICAGO -- Two novel drugs showed promise for blood pressure (BP) lowering in people with treatment-resistant hypertension, according to research presented at the American Heart Association (AHA) ...
Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...
A new study led by scientists at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, demonstrates that aldosterone, a hormone produced in the ...
Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...
In this rapidly evolving setting, clinicians are weighing the alleged harm of continuing these medications in patients for whom ACE inhibitors and ARBs have known benefit against the harm to their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results